Abstract Objective Although SARS-CoV-2 primarily targets the respiratory system, there is evidence that it can also infect the central nervous system, especially in children, leading to neurological symptoms and long-term consequences. It is imperative to summarize the possible mechanisms, main symptoms, and treatments of neurological symptoms of COVID-19 in children. Methods We performed a literature search using the PubMed online database to find studies investigating the mechanisms of COVID-19 infection of the central nervous system and therapies for COVID-19 neurological symptoms in children. Results The main mechanisms of action of SARS-CoV-2 virus on the nervous system are direct invasion, systemic inflammation and molecular mimicry. Although the incidence of adverse reactions to intravenous IgG therapy (IVIG) varies greatly and the contraindications are not yet clear, IVIG has been shown to be clearly effective for the neurological symptoms of COVID-19 in children. Conclusion However, due to insufficient data, more clinical studies are still needed to confirm its safety and efficacy, further improve the treatment plan, and determine the appropriate dosage to better serve clinical practice. Significance The specific regimen of IVIG treatment for COVID-19 in children was explored, which further improved the understanding of COVID-19 and L-C19 neurological diseases in children. Open access: https://akjournals.com/view/journals/2060/112/1/article-p12.xml
They don't mention ME/CFS, only chronic fatigue, the symptom and say for example: Exercise therapy usually has no significant effect on chronic fatigue [55], with amantadine being the most commonly prescribed drug for its treatment, constituting approximately 53.8% of fatigue prescriptions [56]. The reference for the exercise part is: 55.↑ Twomey R, DeMars J, Franklin K, Culos-Reed SN, Weatherald J, Wrightson JG. Chronic fatigue and postexertional malaise in people living with long COVID: an observational study. Phys Ther 2022; 102(4): pzac005. https://doi.org/10.1093/ptj/pzac005.
So, if you are a child with Long covid in Jining, (between Shanghai and Beijing), perhaps you are likely to be taken seriously and not be pushed into GET. This looks like a student doctor project at the Affiliated Hospital of Jining Medical University. I was interested to see more about the amantadine that constitutes 'approximately 53.8% of fatigue prescriptions'. (see Wyva's post above). 56.↑Liu EN, Yang JH, Patel L, Arora J, Gooding A, Ellis R, et al. Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19. J Neurol 2023; 270(10): 4661–72. https://doi.org/10.1007/s00415-023-11885-x. Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19 I've made a thread for the paper: Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19, 2023, Liu et al It has a paywall, amantidine isn't mentioned in the abstract. It's a report of a fairly small study following patients with post-Covid-19 neurological symptoms. So, it would be more accurate to say 'amantadine was being widely used for post-Covid-19 fatigue in San Diego in the early years of the pandemic'.
(Amantadine: Amantadine is an antiviral medicine that blocks the actions of viruses in your body. Amantadine is used to treat Parkinson's disease and "Parkinson-like" symptoms such as stiffness or tremors, shaking, and repetitive uncontrolled muscle movements that may be caused by the use of certain drugs. Amantadine is also used to treat or prevent influenza A in adults and children. It may not be effective during every flu season because certain strains of the virus may be resistant to amantadine. )
I've made a post summarising the information we have on the forum about amantadine here: Antivirals as ME/CFS or Long Covid treatments (e.g. valacyclovir, valgancyclovir, amantadine)